Athos Capital’s Aspire Biopharma Warrant ASBPW Stock Holding History

Athos Capital’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1K	Hold	21,383	–	–	﹤0.01%	44
2025 Q4	$3K	Buy	+21,383	New	+$659	﹤0.01%	37
2025 Q3	–	Sell	-21,383	Closed	-$6K	–	48
2025 Q2	$6K	Hold	21,383	–	–	0.01%	35
2025 Q1	$12K	Hold	21,383	–	–	0.01%	41
2024 Q4	$246K	Hold	21,383	–	–	0.11%	29
2024 Q3	$261K	Hold	21,383	–	–	0.08%	25
2024 Q2	$241K	Hold	21,383	–	–	0.13%	31
2024 Q1	$236K	Hold	21,383	–	–	0.25%	31
2023 Q4	$233K	Hold	21,383	–	–	0.26%	29
2023 Q3	$232K	Sell	21,383 -3,616	-14%	-$292	0.12%	45
2023 Q2	$264	Hold	24,999	–	–	0.21%	58
2023 Q1	$262K	Hold	24,999	–	–	0.18%	72
2022 Q4	$257K	Buy	+24,999	New	+$1.68K	0.15%	90

Other funds holding ASBPW

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Athos Capital's ASBPW Position: Q1 2026 in Review

Athos Capital held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 21,383 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #44.

Athos Capital first reported a position in ASBPW in Q4 2022 and has held it in 13 quarters since. The position peaked at $262K in Q1 2023. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

Athos Capital held 21,383 shares of Aspire Biopharma Warrant worth $1K as of Q1 2026.
Athos Capital left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Athos Capital's portfolio in Q1 2026, its #44 holding.
Athos Capital first reported a position in Aspire Biopharma Warrant in Q4 2022 and has held it in 13 quarters since.
Athos Capital's Aspire Biopharma Warrant position peaked at $262K in Q1 2023.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Athos Capital's 13F filing for Q1 2026, filed 13 May 2026.